Safety of low-dose anticoagulation in extracorporeal membrane oxygenation using the Permanent Life Support System: a retrospective observational study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Bleeding and thrombosis are major complications associated with high mortality in extracorporeal membrane oxygenation (ECMO) management. Anticoagulant therapy should be adequate to reduce thrombosis. However, related studies are limited. Methods: We retrospectively reviewed all patients supported with ECMO at a single institution between January 2014 and July 2022 and included those on all types of ECMO using the Permanent Life Support System. Patients were classified into two groups according to their measured mean activated partial thromboplastin time (aPTT) during ECMO management: a high-anticoagulation (AC) group (aPTT, ≥55 seconds; n=52) and a low-AC group (aPTT, <55 seconds; n=79). The primary outcome was thrombotic or bleeding events during ECMO. Results: We identified 10 patients with bleeding; significantly more of these patients were in the high-AC group (n=8) than in the low-AC group (15.4% vs. 2.5%, p=0.01). However, thrombus events and oxygenator change-free times were not significantly different between the two groups. Four patients in the high-AC group died of bleeding complications (brain hemorrhage, two; hemopericardium, one; and gastrointestinal bleeding, one). One patient in the low-AC group developed a thrombus and died of ECMO dysfunction due to circuit thrombosis. Conclusion: Heparin did not significantly improve thrombotic outcomes. However, maintaining an aPTT of ≥55 seconds was a significant risk factor for bleeding events, especially those associated with mortality.
Abstract
Background: Bleeding and thrombosis are major complications associated with high mortality in extracorporeal membrane oxygenation (ECMO) management. Anticoagulant therapy should be adequate to reduce thrombosis. However, related studies are limited. Methods: We retrospectively reviewed all patients supported with ECMO at a single institution between January 2014 and July 2022 and included those on all types of ECMO using the Permanent Life Support System. Patients were classified into two groups according to their measured mean activated partial thromboplastin time (aPTT) during ECMO management: a high-anticoagulation (AC) group (aPTT, ≥55 seconds; n=52) and a low-AC group (aPTT, <55 seconds; n=79). The primary outcome was thrombotic or bleeding events during ECMO. Results: We identified 10 patients with bleeding; significantly more of these patients were in the high-AC group (n=8) than in the low-AC group (15.4% vs. 2.5%, p=0.01). However, thrombus events and oxygenator change-free times were not significantly different between the two groups. Four patients in the high-AC group died of bleeding complications (brain hemorrhage, two; hemopericardium, one; and gastrointestinal bleeding, one). One patient in the low-AC group developed a thrombus and died of ECMO dysfunction due to circuit thrombosis. Conclusion: Heparin did not significantly improve thrombotic outcomes. However, maintaining an aPTT of ≥55 seconds was a significant risk factor for bleeding events, especially those associated with mortality.
참고문헌 (19)
- McMichael AB, "2021 ELSO adult and pediatric anticoagulation guidelines", ASAIO J, 68, pp.303~310 (2022)
- Sklar MC, "Anticoagulation practices during venovenous extracorporeal membrane oxygenation for respiratory failure. A systematic review", Ann Am Thorac Soc, 13, pp.2242~2250 (2016)
- Wood KL, "Venoarterial-extracorporeal membrane oxygenation without routine systemic anticoagulation decreases adverse events", Ann Thorac Surg, 109, pp.1458~1466 (2020)
- Lv X, "Low vs standardized dose anticoagulation regimens for extracorporeal membrane oxygenation : a meta-analysis", PLoS One, 16, pp.e0249854~ (2021)
- Aubron C, "Low-dose versus therapeutic anticoagulation in patients on extracorporeal membrane oxygenation : a pilot randomized trial", Crit Care Med, 47, pp.e563~71 (2019)
- 변정현, "Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy", Blood Research, 51(3), pp.171~174 (2016), 대한혈액학회
- Sy E, "Anticoagulation practices and the prevalence of major bleeding, thromboembolic events, and mortality in venoarterial extracorporeal membrane oxygenation : a systematic review and meta-analysis", J Crit Care, 39, pp.87~96 (2017)
- Raiten JM, "Anticoagulation and transfusion therapy in patients requiring extracorporeal membrane oxygenation", J Cardiothorac Vasc Anesth, 31, pp.1051~1059 (2017)
- Annich GM, "Thromboprophylaxis in extracorporeal circuits : current pharmacological strategies and future directions", Am J Cardiovasc Drugs, 17, pp.425~439 (2017)
- Tomasko J, "Therapeutic anticoagulation-free extracorporeal membrane oxygenation as a bridge to lung transplantation", J Heart Lung Transplant, 35, pp.947~948 (2016)
- Krueger K, "Venovenous extracorporeal membrane oxygenation with prophylactic subcutaneous anticoagulation only : an observational study in more than 60 patients", Artif Organs, 41, pp.186~192 (2017)
- Buscher H, "Blood and anticoagulation management in extracorporeal membrane oxygenation for surgical and nonsurgical patients : a single-center retrospective review", J Cardiothorac Vasc Anesth, 31, pp.869~875 (2017)
- Pieri M, "Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation : a case-control study", J Cardiothorac Vasc Anesth, 27, pp.30~34 (2013)
- Lazzara RR, "Extracorporeal membrane oxygenation for adult post cardiotomy cardiogenic shock using a heparin bonded system", ASAIO J, 39, pp.M444~7 (1993)
- Lamarche Y, "Thromboembolic events in patients on extracorporeal membrane oxygenation without anticoagulation", Innovations(Phila), 5, pp.424~429 (2010)
- Chung YS, "Is stopping heparin safe in patients on extracorporeal membrane oxygenation treatment?", ASAIO J, 63, pp.32~36 (2017)
- Zangrillo A, "A meta-analysis of complications and mortality of extracorporeal membrane oxygenation", Crit Care Resusc, 15, pp.172~178 (2013)
- Lequier L, "Extracorporeal membrane oxygenation circuitry", Pediatr Crit Care Med, 14(5 Suppl 1), pp.S7~12 (2013)
- Yeo HJ, "Low-dose heparin during extracorporeal membrane oxygenation treatment in adults", Intensive Care Med, 41, pp.2020~2021 (2015)